Project Grant R21AI180963
Award Date
5/14/24
Completion Date
3/31/26
Dollars Obligated
$839K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94110, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products/services being delivered include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect live Mycobacterium tuberculosis (MTB) and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $817,405 to Colorado State University to develop new 3-4 drug regimens containing the spectinamide antibiotic administered via inhalation for the treatment of drug-sensitive and multidrug-resistant tuberculosis (TB). The key objectives are to: 1) manufacture and characterize larger quantities of the spectinamide dry...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new classes of pyrazinoic acid prodrugs to combat Mycobacterium tuberculosis (MTB) infection, including strains resistant to the current first-line drug pyrazinamide (PZA). The $813,373 award, granted on June 2, 2025, will support research at Rutgers, The State University of New Jersey to characterize MTB's...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $265,650 to support research focused on developing novel medicinal chemistry strategies to overcome drug-resistant tuberculosis (TB). The primary goal is to establish the structure-activity relationship and mechanism of action of a series of C25-modified rifabutin analogs that have demonstrated potent...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,516 to Vanderbilt University Medical Center (VUMC) to conduct clinical pharmacology research on short-course rifapentine for tuberculosis (TB) prevention. The key objectives are to: 1) confirm that model-informed doses of TB and HIV drugs achieve target exposures in priority populations like people living with...
The federal Project Grant award of $647,922.00, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program), supports the development of a clinical decision support tool to optimize the selection of antibiotics for patients with rifampicin-resistant tuberculosis (RR-TB). The project aims to leverage spatiotemporal machine learning and decision models to synthesize data from clinical trials, local surveillance systems, and...
This Project Grant award of $193,375.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports a research project to investigate the impact of genetic variations in the ESX1 secretion system of Mycobacterium tuberculosis on drug treatment outcomes. The primary objectives are to use bacterial genetic approaches to assess the effects of clinically prevalent ESX1 variants on system function in vitro,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 aims to develop a platform for detecting genetic antibiotic resistance motifs that can predict current and future susceptibility to therapeutics. The project will establish the feasibility of leveraging mutational signatures in bacterial DNA to identify antibiotic resistance status, including the potential for rapid development of multi-drug resistance. This approach...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to The Washington University to develop a new series of nitro-containing 1,2,4-triazole compounds and related pyrrolidine compounds as potential treatments for tuberculosis (TB). The research aims to identify compounds that can inhibit drug-resistant strains of Mycobacterium tuberculosis (MTB) through a unique...
This $233,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid point-of-care assays for detecting antibiotic resistance in the bacteria that causes syphilis, Treponema pallidum. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care loop-mediated isothermal amplification (LAMP) assay to detect single nucleotide...